Kristen N Ganjoo
Professor of Medicine (Oncology)
Medicine - Oncology

Curriculum Vitae available Online  Resume available Online

CLINICAL OFFICES
• Stanford Comprehensive Cancer Center
  875 Blake Wilbur Dr
  MC 5826
  Stanford, CA 94305
  Tel  (650) 498-6000  Fax  (650) 725-3321

Bio

CLINICAL FOCUS
• Cancer > Sarcoma
• Soft Tissue Sarcoma
• Gastrointestinal Stromal Tumors
• Ewing's Sarcoma
• Osteosarcoma
• Medical Oncology
• Uterine leiomyosarcoma
• Leiomyosarcoma
• Liposarcoma
• Synovial sarcoma

ACADEMIC APPOINTMENTS
• Professor - University Medical Line, Medicine - Oncology
• Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS
• Assistant Professor of Medicine, Indiana University, (2000-2004)
• Assistant Professor of Medicine, Stanford University, (2004-2015)
• Associate Professor of Medicine, Stanford University, (2015- present)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS
• Associate Member, American Society of Clinical Oncology (1998 - present)
• Investigator, Sarcoma Alliance for Research through Collaboration (SARC) (2008 - present)
• Physician Leader, Stanford Cancer Center- Sarcoma (2008 - present)
• Board Member, National Comprehensive Cancer Network Task Force (NCCN)-Soft Tissue Sarcoma (2009 - present)
• Clinical Research Group Leader-Sarcoma, Stanford University (2010 - present)
• Member, Connective Tissue Oncology Society (CTOS) (2010 - present)
• Member, Institutional Review Board- Stanford (2012 - present)
• Member, Scientific Review Board- Stanford Cancer Institute (2013 - present)

PROFESSIONAL EDUCATION
• Board Certification: Medical Oncology, American Board of Internal Medicine (2023)
• Fellowship: Indiana University School Of Medicine (2000) IN
• Residency: Indiana University (1997) IN
• Internship: Indiana University (1995) IN
• Medical Education: University of South Alabama Medical Center (1994) AL
• BS, UC Davis , Biological Sciences (1989)

LINKS
• Get a Second Opinion: https://stanfordhealthcare.org/second-opinion/overview.html

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS
Clinical research with new and novel therapies for sarcomas including anti-angiogenesis agents and targeted agents.

CLINICAL TRIALS
• A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS), Recruiting
• ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma, Recruiting
• Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1), Recruiting
• Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma, Recruiting
• Study of Cryoablation and Nirogacestat for Desmoid Tumor, Recruiting
• Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor, Recruiting
• 18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma, Not Recruiting
• A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa, Not Recruiting
• A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies, Not Recruiting
• A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma, Not Recruiting
• A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib, Not Recruiting
• A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma, Not Recruiting
• A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma, Not Recruiting
• A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma, Not Recruiting
• ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer, Not Recruiting
• Adoptive Cell Therapy Long-term Follow-up (LTFU) Study, Not Recruiting
• Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma, Not Recruiting
• Cabozantinib for Adults With Advanced Soft Tissue Sarcoma, Not Recruiting
• Cytoreductive Surgery & HIPEC w/Gemcitabine + Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma, Not Recruiting
• Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics), Not Recruiting
• Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma, Not Recruiting
• Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation, Not Recruiting
• Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma, Not Recruiting
• Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors, Not Recruiting
• Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors, Not Recruiting
• Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenonosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor, Not Recruiting
• Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma, Not Recruiting
• Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST), Not Recruiting
• Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies, Not Recruiting
• Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS), Not Recruiting
• Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma, Not Recruiting
• Phase 3 Study to Treat Patients With Soft Tissue Sarcomas, Not Recruiting
• Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma, Not Recruiting
• Safety Study of MGD009 in B7-H3-expressing Tumors, Not Recruiting
• SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes, Not Recruiting
• Selinexor in Advanced Liposarcoma, Not Recruiting
• Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor, Not Recruiting
• Study of Denosumab in Subjects With Giant Cell Tumor of Bone, Not Recruiting
• Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002), Not Recruiting
• Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery, Not Recruiting
• Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma, Not Recruiting

Publications

PUBLICATIONS

• Feasibility of Longitudinal ctDNA Assessment in Patients with Uterine and Extra-Uterine Leiomyosarcoma. Cancers
  Zhou, M., Bui, N., Rathore, R., Sudhaman, S., George, G. V., Malashevich, A. K., Malhotra, M., Liu, M. C., Aleshin, A., Ganjoo, K. N.
  2022; 15 (1)

• Management of Patients with Newly Diagnosed Desmoid Tumors in a First-Line Setting. Cancers
  Testa, S., Bui, N. Q., Charville, G. W., Avedian, R. S., Steffner, R., Ghanouni, P., Mohler, D. G., Ganjoo, K. N.
  2022; 14 (16)

• Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma CANCERS
  Pan, M., Trieu, M. K., Sidhu, M., Yu, J., Seto, T., Ganjoo, K.
  2021; 13 (8)

• Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review IMMUNOTHERAPY
  Zhou, M., Bui, N., Bolleddu, S., Lohman, M., Becker, H., Ganjoo, K.
• **NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021.** *Journal of the National Comprehensive Cancer Network: JNCCN*
  von Mehren, M., Kane, J. M., Bui, M. M., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Homsi, J., Keedy, V., Kelly, et al
  2020; 18 (12): 1604–12

• **Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas** *JCO Precision Oncology*
  Przybyl, J., Spans, L., Lum, D. A., Zhu, S., Vennam, S., Forgo, E., Varma, S., Ganjoo, K., Hastie, T., Bowen, R., Debie-Rychter, M., van de Rijn, M.
  2019; 3

• **Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma** *Clinical Cancer Research*
  Przybyl, J., Chabon, J. J., Spans, L., Ganjoo, K. N., Vennam, S., Newman, A. M., Forgo, E., Varma, S., Zhu, S., Debie-Rychter, M., Alizadeh, A. A., Diehn, M., van de Rijn, et al
  2018; 24 (11): 2688–99

• **Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma** *Journal of Clinical Oncology*
  Chawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., Butrynski, J. E., Adkins, D. R., Hendifar, A. E., Kroll, S., Ganjoo, K. N.
  2014; 32 (29): 3299–?

• **A Phase 2 Trial of R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients With Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas Results of a Sarcoma Alliance for Research Through Collaboration Study** *Cancer*
  Pappo, A. S., Vassal, G., Crowley, J. J., Bolejack, V., Hogendoorn, P. C., Chugh, R., Ladanyi, M., Grippo, J. F., Dall, G., Staddon, A. P., Chawla, S. P., Maki, R. G., Araujo, et al
  2014; 120 (16): 2448-2456

• **Gastrointestinal stromal tumors, version 2.2014.** *Journal of the National Comprehensive Cancer Network*
  von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, et al
  2014; 12 (6): 853-862

• **Soft Tissue Sarcoma, Version 2.2014 Featured Updates to the NCCN Guidelines** *Journal of the National Comprehensive Cancer Network*
  von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, et al
  2014; 12 (4): 473-483

• **A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.** *Annals of Oncology*
  Ganjoo, K. N., Villalobos, V. M., Kamaya, A., Fisher, G. A., Butrynski, J. E., Morgan, J. A., Wagner, A. J., D'adamo, D., McMillan, A., Demetri, G. D., George, S.
  2014; 25 (1): 236-240

• **R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study** *Journal of Clinical Oncology*
  Pappo, A. S., Patel, S. R., Crowley, J., Reinke, D. K., Kuenkele, K., Chawla, S. P., Toner, G. C., Maki, R. G., Meyers, P. A., Chugh, R., Ganjoo, K. N., Schuetze, S. M., Juergens, et al
  2011; 29 (34): 4541-4547

• **Current and Emerging Pharmacological Treatments for Gastrointestinal Stromal Tumour** *Drugs*
  Ganjoo, K. N., Patel, S.
  2011; 71 (3): 321-330

• **A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma** *Oncology*
  Ganjoo, K. N., Cranmer, L. D., Butrynski, J. E., Rushing, D., Adkins, D., Okuno, S. H., Lorent, G., Kroll, S., Langmuir, V. K., Chawla, S. P.
  2011; 80 (1-2): 50-56

• **New Developments in Targeted Therapy for Soft Tissue Sarcoma** *Current Oncology Reports*
  Ganjoo, K. N.
  2010; 12 (4): 261-265
• **Soft Tissue Sarcoma** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Demetri, G. D., Antonia, S., Benjamin, R. S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., Heslin, M. J., Hutchinson, R. J., Kane, J. M., Letson, G. D., McGarry, et al
  2010; 8 (6): 630-674

• **NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Demetri, G. D., von Mehren, M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., Maki, R. G., Pisters, P. W., Raut, C. P., Riedel, R. F., Schuetze, S., Sundar, H. M., Trent, J. C., Wayne, et al
  2010; 8: S1-S43

• **Antiangiogenesis Agents in the Treatment of Soft Tissue Sarcomas** *CANCER*
  Ganjoo, K., Jacobs, C.
  2010; 116 (5): 1177-1183

• **Trabectedin: an anticancer drug from the sea** *EXPERT OPINION ON PHARMACOTHERAPY*
  Ganjoo, K. N., Patel, S. R.
  2009; 10 (16): 2735-2743

• **Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec** *LEUKEMIA & LYMPHOMA*
  Ganjoo, K. N., Demetri, G. D., Jacobs, C., Patel, S.
  2009; 50 (11): 1882-1884

• **Management Strategies and Outcomes in Primary Liver Angiosarcoma.** *American journal of clinical oncology*
  Ramakrishnan, N., Mokhtari, R., Charville, G. W., Bui, N., Ganjoo, K.
  2023

• **Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis.** *Cancer research communications*
  Testa, S., Bui, N. Q., Ganjoo, K. N.
  2023; 3 (7): 1212-1223

• **Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy.** *International journal of molecular sciences*
  Zhou, M. Y., Bui, N. Q., Charville, G. W., Ganjoo, K. N., Pan, M.
  2023; 24 (11)

• **A Retrospective Multi-Institutional Cohort Analysis of Clinical Characteristics and Outcomes in Dedifferentiated Chondrosarcoma.** *Cancers*
  Bui, N., Dietz, H., Farag, S., Hirbe, A. C., Wagner, M. J., Van Tine, B. A., Ganjoo, K., Jones, R. L., Keedy, V. L., Davis, E. J.
  2023; 15 (9)

• **Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
  Bui, N. Q., Nemat-Gorgani, N., Subramanian, A., Torres, I. A., Lohman, M., Sears, T. J., van de Rijn, M., Charville, G. W., Becker, H. C., Wang, D. S., Hwang, G. L., Ganjoo, K. N., Moding, et al
  2023

• **PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)**
  Rodon, J., Demeure, M., Deming, D., Federman, N., Mckean, M., Lee, E., Spira, A., Kwiatkowski, D., Hussein, M., Gordon, E., Crockett, D., Ganjoo, K., Schulte, et al
  BMJ PUBLISHING GROUP.2022: A231-A232

• **Long-term Outcomes of Diffuse or Recurrent Tenosynovial Giant Cell Tumor Treated with Postoperative External Beam Radiation Therapy.** *Practical radiation oncology*
  Daniel, C., Yoo, C. H., Jiang, A., van Eyben, R., Mohler, D. G., Ganjoo, K., Bui, N., Donaldson, S. S., Million, L., Rijn, M. v., Moon Oh, J., Hiniker, S. M.
  2022

• **Enrollment of pediatric and adolescent patients with MAGE-A4+advanced synovial sarcoma into cohort 2 of SPEARHEAD-1: a phase 2 trial of afamitresgene autoleucel (“afami-cel” [formerly ADP-A2M4])**
  Lunt, C., D'Angelo, S. P., Razak, A., Wagner, M. J., Van Tine, B. A., Ganjoo, K., Blay, J., Araujo, D. M., Agulnik, M., Glod, J. W., Van Winkle, E., Elefant, E., Biswas, et al
**Interactions in CSF1-driven Tenosynovial Giant Cell Tumors.** Clinical cancer research : an official journal of the American Association for Cancer Research
van IJzendoorn, D. G., Matusiak, M., Charville, G. W., Spierenburg, G., Varma, S., Colburg, D. R., van de Sande, M. A., van Langevelde, K., Mohler, D. G., Ganjoo, K. N., Bui, N. Q., Avedian, R. S., Bovee, et al
2022

**Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN.** Clinical orthopaedics and related research
Healey, J. H., Tap, W. D., Gelhorn, H. L., Ye, X., Speck, R. M., Palmerini, E., Stucchiotti, S., Desai, J., Wagner, A. J., Alcindor, T., Ganjoo, K., Martin-Broto, J., Wang, et al
2022

**A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results.** Cancer medicine
Attia, S., Bolejack, V., Ganjoo, K. N., George, S., Agulnik, M., Rushing, D., Loggers, E. T., Livingston, M. B., Wright, J., Chawla, S. P., Okuno, S. H., Reinke, D. K., Riedel, et al
2022

**Cutaneous Angiosarcoma of the Head and Neck-A Retrospective Analysis of 47 Patients.** Cancers
Ramakrishnan, N., Mokhtari, R., Charville, G. W., Bui, N., Ganjoo, K.
2022; 14 (15)

**First Recurrence of Synovial Sarcoma Presenting With Solitary Pancreatic Mass** CUREUS JOURNAL OF MEDICAL SCIENCE
Narayan, R. R., Charville, G. W., Delitto, D., Ganjoo, K. N.
2022; 14 (6)

**First Recurrence of Synovial Sarcoma Presenting With Solitary Pancreatic Mass.** Cureus
Narayan, R. R., Charville, G. W., Delitto, D., Ganjoo, K. N.
2022; 14 (6): e26356

**nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program.** LIPPINCOTT WILLIAMS & WILKINS.2022
Dickson, M., Ravi, V., Riedel, R. F., Ganjoo, K. N., Van Tine, B., Chugh, R., Cranmer, L. D., Gordon, E., Chen, J., Murphy, M., Schmid, A. N., Desai, N., Palma, et al

**Local control outcomes using stereotactic body radiotherapy or surgical resection for metastatic sarcoma.** International journal of radiation oncology, biology, physics
Gutkin, P. M., von Eyben, R., Chin, A., Donaldson, S. S., Oh, J., Jiang, A., Ganjoo, K. N., Avedian, R. S., Bruzoni, M., Steffner, R. J., Moding, E. J., Hiniker, S. M.
2022

**Current management and recent progress in desmoid tumors.** Cancer treatment and research communications
Zhou, M. Y., Bui, N. Q., Charville, G. W., Ghanouni, P., Ganjoo, K. N.
2022; 31: 100562

**Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Gouder, M. M., Razak, A. A., Somaiah, N., Chawla, S., Martin-Broto, J., Grignani, G., Schuetze, S. M., Vincenzi, B., Wagner, A. J., Chmielewski, B., Jones, R. L., Riedel, R. F., Stucchiotti, et al
2022: ICO2101829

**Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.** JAMA oncology
Jones, R. L., Ravi, V., Brohl, A. S., Chawla, S., Ganjoo, K. N., Italiano, A., Attia, S., Burgess, M. A., Thornton, K., Cranmer, L. D., Cheang, M. C., Liu, L., Robertson, et al
2022

**Post-operative Stereotactic Radiosurgery of Malignant Melanotic Schwannoma.** Cureus
Hall, J. C., Chang, S. D., Wilson, T. J., Ganjoo, K. N., Toland, A., Vogel, H., Polom, E. L., Rahimy, E.
2022; 14 (3): e22849
• Detection of MDM2 amplification by shallow whole genome sequencing of cell-free DNA of patients with dedifferentiated liposarcoma. *PloS one*
  Przybyl, J., Spans, L., Ganjoo, K., Bui, N., Mohler, D., Norton, J., Poultsides, G., Debiee-Rychter, M., van de Rijn, M.
  2022; 17 (1): e0262272

• NCCN Guidelines Insights: Gastrointestinal Stromal Tumors, Version 2.2022. *Journal of the National Comprehensive Cancer Network : JNCCN*
  von Mehren, M., Kane, J. M., Riedel, R. F., Sicklick, J. K., Pollack, S. M., Agulnik, M., Bui, M. M., Carr-Archer, J., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., Gonzalez, et al
  2022; 20 (11): 1204-1214

• Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network : JNCCN*
  von Mehren, M., Kane, J. M., Agulnik, M., Bui, M. M., Carr-Archer, J., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., Gonzalez, R. J., Holder, A., Homsi, J., Keedy, et al
  2022; 20 (7): 815-833

• Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas. *Cancers*
  Testa, S., Bui, N. Q., Wang, D. S., Louie, J. D., Sze, D. Y., Ganjoo, K. N.
  2022; 14 (2)

• Genomic Predictors of Recurrence Patterns in Localized Soft Tissue Sarcoma Treated With Radiation Therapy. *International journal of radiation oncology, biology, physics*
  Devine, M., Chin, A. L., Million, L., Ganjoo, K. N., Bui, N. Q., Moding, E. J.
  2021; 111 (35): e316

• Genomic Predictors of Recurrence Patterns in Localized Soft Tissue Sarcoma Treated With Radiation Therapy
  Devine, M., Chin, A. L., Million, L., Ganjoo, K. N., Bui, N. Q., Moding, E. J.
  ELSEVIER SCIENCE INC.2021; E316

• Clinical activity of single-agent cabozantinib (XL184), a multi-receptor tyrosine kinase inhibitor, in patients with refractory soft tissue sarcomas. *Clinical cancer research : an official journal of the American Association for Cancer Research*
  O'Sullivan Coyne, G., Kummar, S., Hu, J., Ganjoo, K., Chow, W. A., Do, K. T., Zlott, J., Bruns, A., Rubinstein, L., Foster, J. C., Jawara, L., Meehan, R., Piekarz, et al
  2021

• Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer
  Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M., Alves, N., Rogers, B., Neal, J. W., Fan, A. C., Parikh, D., Patel, M. I., Shah, S., Srinivas, et al
  LIPPINCOTT WILLIAMS & WILKINS.2021

• Safety and Feasibility of Cryoablation during Immunotherapy in Patients with Metastatic Soft Tissue Sarcoma. *Journal of vascular and interventional radiology : JVIR*
  Doshi, A., Zhou, M., Bui, N., Wang, D. S., Ganjoo, K., Hwang, G. L.
  2021

• Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. *European journal of cancer (Oxford, England : 1990)*
  George, S., Chi, P., Heinrich, M. C., von Mehren, M., Jones, R. L., Ganjoo, K., Trent, J., Gelderblom, H., Razak, A. A., Gordon, M. S., Somaiah, N., Jennings, J., Meade, et al
  2021; 155: 236-244

• Dermatopathological review of cutaneous squamous cell carcinoma events in patients with gastrointestinal stromal tumors treated with ripretinib
  Patel, A., George, S., Janku, F., Ganjoo, K., Young, R., Chi, P., Westwood, D., Stearns, S., Meade, J., Ruiz-Soto, R., Lacouture, M.
  ELSEVIER.2021: S134-S135

• Skin angiography assisted mastectomy in secondary breast angiosarcoma: Complete clinical response after neoadjuvant immunotherapy. *The breast journal*
  Ju, T., Foster, D., Titan, A., Najjar, S., Bean, G. R., Ganjoo, K., Wapnir, I.
  2021

• Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.
IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).
D’Angelo, S. P., Noujaim, J., Thistlethwaite, F., Razak, A., Stacchiotti, S., Chow, W., Haanen, J. G., Chalmers, A., Robinson, S., Van Tine, B., Ganjoo, K. N., Johnson, M. L., Chiu, et al
LIPPINCOTT WILLIAMS & WILKINS.2021

Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations.
Dickson, M., Ravi, V., Ganjoo, K. N., Iyer, G.
LIPPINCOTT WILLIAMS & WILKINS.2021

P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).
Schuetze, S., Ballman, K. V., Ganjoo, K. N., Davis, E. J., Morgan, J. A., Tinoco, G., Burgess, M., Van Tine, B., Choy, E., Shepard, D., Kelly, C., Riedel, R. F., von Mehren, et al
LIPPINCOTT WILLIAMS & WILKINS.2021

Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial ACTA ORTHOPAEDICA
van de Sande, M., Tap, W. D., Gelhorn, H. L., Ye, X., Speck, R. M., Palmerini, E., Stacchiotti, S., Desai, J., Wagner, A. J., Alcindor, T., Ganjoo, K., Martin-Broto, J., Wang, et al
2021

Rare and fatal complication of immune checkpoint inhibition: a case report of haemophagocytic lymphohistiocytosis with severe lichenoid dermatitis. British journal of haematology
Choi, S., Zhou, M., Bahrami, E., Martin, B. A., Ganjoo, K. N., Zaba, L. C.
2021

Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report. The Permanente journal
Pan, M., Ganjoo, K., Karam, A.
2021; 25

Evaluation of Absolute Lymphocyte Count at Diagnosis and Mortality Among Patients With Localized Bone or Soft Tissue Sarcoma. JAMA network open
Brewster, R., Purington, N., Henry, S., Wood, D., Ganjoo, K., Bui, N.
2021; 4 (3): e210845

Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression. Case reports in oncology
Zhou, M., Bui, N., Lohman, M., van de Rijn, M., Hwang, G., Ganjoo, K.
2021; 14 (1): 459–65

A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma. Current oncology (Toronto, Ont.)
Testa, S., Hu, B. D., Saadeh, N. L., Pribrnow, A., Spunt, S. L., Charville, G. W., Bui, N. Q., Ganjoo, K. N.
2021; 28 (6): 5304-5317

Surgical resection of leiomyosarcoma of the inferior vena cava: A case series and literature review. Surgical oncology
Zhou, M., Javadi, C., Charville, G. W., Bui, N. Q., Harris, E. J., Poultsides, G. A., Norton, J. A., Visser, B., Lee, B., Dua, M. M., Ganjoo, K. N.
2021; 39: 101670

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Wagner, A. J., Ravi, V., Riedel, R. F., Ganjoo, K., Van Tine, B. A., Chugh, R., Cranmer, L., Gordon, E. M., Hornick, J. L., Du, H., Grigorian, B., Schmid, A. N., Hou, et al
2021: ICO2101728

Fusion and rearrangement (RE) detection using DNA and RNA-based comprehensive genomic profiling (CGP) of sarcomas
Ganjoo, K., Madison, R., Rosenzweig, M., Oxnard, G., Venstrom, J., Ward, A., Schrock, A. B.
ELSEVIER.2021: S1116-S1117
• Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Chawla, S. P., Van Tine, B. A., Pollack, S. M., Ganjoo, K. N., Elias, A. D., Riedel, R. F., Attia, S., Choy, E., Okuno, S. H., Agulnik, M., von Mehren, M., Livingston, M. B., Keedy, et al
  2021: JCO2003452

• Management Strategies for Patients With Epithelioid Hemangioendothelioma: Charting an Indolent Disease Course. *American journal of clinical oncology*
  Yurkiewicz, I. R., Zhou, M., Ganjoo, K. N., Charville, G. W., Bolleddu, S., Lohman, M., Bui, N.
  2021

• Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I
  Janku, F., Chi, P., Heinrich, M., von Mehren, M., Jones, R. L., Ganjoo, K., Trent, J., Gelderblom, H., Razak, A., Gordon, M., Somaiah, N., Jennings, J., Shi, et al
  ELSEVIER.2020: S974–S975

• Switch Control Inhibition of KIT and PDGFRα in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Janku, F., Abdul Razak, A. R., Chi, P., Heinrich, M. C., von Mehren, M., Jones, R. L., Ganjoo, K., Trent, J., Gelderblom, H., Somaiah, N., Hu, S., Rosen, O., Su, et al
  2020: JCO2000522

• A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib vs. Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. *The oncologist*
  Riedel, R. F., Ballman, K. V., Attia, S., Loggers, E. T., Ganjoo, K. N., Livingston, M. B., Chow, W., Wright, J., Ward, J. H., Rushing, D., Okuno, S. H., Reed, D. R., Liebner, et al
  2020

• Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registration trial phase II trial, AMPECT.
  Wagner, A. J., Ravi, V., Riedel, R. F., Ganjoo, K. N., Van Tine, B., Chugh, R., Cranmer, L. D., Gordon, E., Hornick, J. L., Kwiatkowski, D. J., Du, H., Grigorian, B., Schmid, et al
  AMER SOC CLINICAL ONCOLOGY.2020

• Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. *JAMA*
  Tap, W. D., Wagner, A. J., Schönknecht, P. n., Martin-Broto, J. n., Krarup-Hansen, A. n., Ganjoo, K. N., Yen, C. C., Abdul Razak, A. R., Spira, A. n., Kawai, A. n., Le Cesne, A. n., Van Tine, B. A., Naito, et al
  2020; 323 (13): 1266–76

• Sinonasal FUS-ERG-Rearranged Ewing's Sarcoma Mimicking Glomangiopericytoma. *Case reports in oncology*
  Zhou, M. n., Ko, Y. C., Charville, G. W., Ganjoo, K. N.
  2020; 13 (3): 1393–96

• Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review. *Immunotherapy*
  Zhou, M. n., Bui, N. n., Bolleddu, S. n., Lohman, M. n., Becker, H. C., Ganjoo, K. n.
  2020

• Angiosarcoma of the Breast: Management and Outcomes. *American journal of clinical oncology*
  Gutkin, P. M., Ganjoo, K. N., Lohman, M. n., von Eyben, R. n., Charville, G. W., Nazerali, R. S., Dirbas, F. M., Horst, K. C.
  2020

• Tenosynovial giant cell tumor of the suboccipital region - A rare, benign neoplasm in this location. *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia*
  Singh, R. n., Stienen, M. N., Ganjoo, K. n., Kolahe, K. S., Cayrol, R. n., Charville, G. W., Born, D. E., Zygourakis, C. C.
  2020

• Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)
  Chi, P., Janku, F., Heinrich, M., Ganjoo, K., Gelderblom, H., Gordon, M., Jones, R., Razak, A., Trent, J., von Mehren, M., Hu, S., Su, Y., Ruiz-Soto, et al
  AMER ASSOC CANCER RESEARCH.2019
• Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas. *JCO precision oncology*
  Przybyl, J., Spans, L., Lum, D. A., Zhu, S., Vennam, S., Forgó, E., Varma, S., Ganjoo, K., Hastie, T., Bowen, R., Debiec-Rychter, M., van de Rijn, M.
  2019; 3

• Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS)
  Jones, R. I., Ravi, V., Brohl, A. S., Chawla, S. P., Ganjoo, K., Italiano, A., Attia, S., Burgess, M., Thornton, K., Cranmer, L., Liu, L., Theuer, C., Maki, et al
  OXFORD UNIV PRESS. 2019: 683

• Ripretinib (DCC-2618) pharmacokinetics (PK) in a Phase I study in patients with gastrointestinal stromal tumors (GIST) and other advanced malignancies: A retrospective evaluation of the PK effects of proton pump inhibitors (PPIS)
  Janku, F., Heinrich, M., Chi, P., Razak, A., von Mehren, M., Gordon, M., Ganjoo, K., Trent, J., Jones, R. L., Gelderblom, H., Running, K., Wang, J., Ruiz-Soto, et al
  AMER ASSOC CANCER RESEARCH. 2019

• ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) plus olaratumab versus dox plus PBO in patients (pts) with advanced soft tissue sarcomas (STS).
  Tap, W. D., Wagner, A. J., Papai, Z., Ganjoo, K. N., Yen, C., Schoffski, P., Razak, A., Martin Broto, J., Spira, A. I., Kawai, A., Krarup-Hansen, A., Le Cesne, A., Van Tine, et al
  AMER SOC CLINICAL ONCOLOGY. 2019

• Uterine sarcomas. *Current problems in cancer*
  Ganjoo, K. N.
  2019

• Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma *JOURNAL OF CLINICAL ONCOLOGY*
  Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., Rushing, D., Okuno, S., Reinke, et al
  2019; 37 (16): 1424–+

• A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1(+) soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.
  Chawla, S. P., Van Tine, B., Pollack, S., Ganjoo, K. N., Elias, A. D., Riedel, R. F., Attia, S., Choy, E., Okuno, S. H., Agulnik, M., von Mehren, M., Livingston, M. B., Keedy, et al
  AMER SOC CLINICAL ONCOLOGY. 2019

• A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.
  Van Tine, B., Bui, N., Prudner, B., Bomalaski, J. S., Wu, B., Chawla, S. P., Ganjoo, K. N., Oppelt, P., Hirbe, A. C.
  AMER SOC CLINICAL ONCOLOGY. 2019

• Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS).
  Bui, N., Dietz, H., Hirbe, A. C., Ganjoo, K. N., Van Tine, B., Keedy, V., Davis, E. J.
  AMER SOC CLINICAL ONCOLOGY. 2019

• ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.
  Wagner, A. J., Ravi, V., Ganjoo, K. N., Van Tine, B., Riedel, R. F., Chugh, R., Cranmer, L. D., Gordon, E., Hornick, J. L., Kwiatkowski, D. J., Du, H., Grigorian, B., Schmid, et al
  AMER SOC CLINICAL ONCOLOGY. 2019

• Responder analysis of patient-reported outcomes measurement information system (PROM'S) physical function (PF) and worst stiffness among patients with tenosynovial giant cell tumors (TGCT) in the ENLIVEN study.
  Tap, W. D., Speck, R. M., Ye, X., Palmerini, E., Stacchiotti, S., Desai, J., Wagner, A. J., Alcindor, T., Ganjoo, K. N., Broto, J., Wang, Q., Shuster, D., Gelhorn, et al
  AMER SOC CLINICAL ONCOLOGY. 2019

• Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., Rushing, D., Okuno, S., Reinke, et al
  2019: JCO1802374
• The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University. *American journal of clinical oncology*  
Kamat, N. V., Million, L., Yao, D., Donaldson, S. S., Mohler, D. G., van de Rijn, M., Avedian, R. S., Kapp, D. S., Ganjoo, K. N.  
2019; 42 (2): 166–71

• Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. *Lancet (London, England)*  
Tap, W. D., Gelderblom, H. n., Palumerini, E. n., Desai, J. n., Bauer, S. n., Blay, J. Y., Alcindor, T. n., Ganjoo, K. n., Martín-Broto, J. n., Ryan, C. W., Thomas, D. M., Peterfy, C. n., Healey, et al  
2019

• A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis. *Clinical sarcoma research*  
Bui, N. Q., Przybyl, J., Trabucco, S. E., Frampton, G., Hastie, T., van de Rijn, M., Ganjoo, K. N.  
2019; 9: 12

• The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University. *American journal of clinical oncology*  
Kamat, N. V., Million, L., Yao, D., Donaldson, S. S., Mohler, D. G., van de Rijn, M., Avedian, R. S., Kapp, D. S., Ganjoo, K. N.  
2018

• The impact of postoperative therapy on primary cardiac sarcoma. *The Journal of thoracic and cardiovascular surgery*  
Wu, Y., Million, L., Moding, E. J., Scott, G., Berry, M., Ganjoo, K. N.  
2018; 156 (6): 2194-2203

• Aldoxorubicin therapy for the treatment of patients with advanced soft tissue sarcoma. *Future Oncology*  
Seetharam, M., Kolla, K. R., Ganjoo, K. N.  
2018; 14 (23): 2323–33

• Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRα inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens. *Annals of oncology : official journal of the European Society for Medical Oncology*  
George, S., Heinrich, M., Chi, P., Razak, A., von Mehren, M., Gordon, M., Ganjoo, K. N., Somaiah, N., Trent, J. C., Rodon Ahnert, J., Wolf, J., Ruiz-Soto, R., Rosen, et al  
2018; 29 Suppl 8: viii576–viii577

• Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRα inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens  
George, S., Heinrich, M., Chi, P., Razak, A., von Mehren, M., Gordon, M., Ganjoo, K. N., Somaiah, N., Trent, J. C., Ahnert, J., Wolf, J., Ruiz-Soto, R., Rosen, et al  
Oxford univ press. 2018

• Pharmacokinetic (PK), safety, and tolerability profile of DCC-2618 in a phase I trial supports 150mg QD selected for a pivotal phase III trial in gastrointestinal stromal tumor (GIST)  
Janku, F., Heinrich, M., Razak, A., von Mehren, M., Gordon, M., Ganjoo, K. N., Chow, W. A., Somaiah, N., Lee, J., Kuida, K., Soto, R., Rosen, O., George, et al  
AMER ASSOC CANCER RESEARCH. 2018

• Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. *JAMA oncolgy*  
Schuetze, S. M., Bolejack, V., Thomas, D. G., von Mehren, M., Patel, S., Samuels, B., Choy, E., D'Amato, G., Staddon, A. P., Ganjoo, K. N., Chow, W. A., Rushing, D. A., Forscher, et al  
2018; 4 (6): 814–20

• CDKN2A deletion as a prognostic marker: A clinico-genomic analysis of sarcoma patients.  
Nam Bui, Przybyl, J., Million, L., Van De Rijn, M., Ganjoo, K. N.  
AMER SOC CLINICAL ONCOLOGY. 2018

• Decreased lymphocyte count at diagnosis as a marker for worse outcome in localized sarcoma.  
Bui, N., Henry, S., Ganjoo, K. N.  
AMER SOC CLINICAL ONCOLOGY. 2018

• Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa).  
Wagner, A. J., Riedel, R. F., Van Tine, B., Chugh, R., Ganjoo, K. N., Cranmer, I. D., Pollack, S., Sankhala, K., Gordon, E., Ravi, V., Hornick, J. L., Kwiatkowski, D. J., Grigorian, et al  
AMER ASSOC CANCER RESEARCH. 2018
A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.
Riedel, R. F., Ballman, K. V., Lu, Y., Attia, S., Loggers, E., Ganjoo, K. N., Livingston, M. B., Chow, W., Wright, J. A., Ward, J., Rushing, D. A., Okuno, S. H., Reed, et al

Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).
Tap, W. D., Gelderblom, H., Stacchiotti, S., Palmerini, E., Ferrari, S., Desai, J., Bauer, S., Blay, J., Alcindor, T., Ganjoo, K. N., Broto, J., Ryan, C. W., Shuster, et al

Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.
George, S., Heinrich, M. C., Razak, A., Chi, P., Gordon, M. S., Ganjoo, K. N., von Mehren, M., Somaiah, N., Trent, J. C., Su, Y., Ruiz-Soto, R., Rosen, O., Janku, et al

Soft Tissue Sarcoma, Version 2.2018 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
von Mehren, M., Randall, R., Benjamin, R. S., Boles, S., Bui, M. M., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, J. M., Keedy, V., Kim, E., Koon, et al

Anaplastic Thyroid Cancer With Extensive Skeletal Muscle Metastases on 18F-FDG PET/CT. Clinical nuclear medicine
Yurkiewicz, I. R., Ganjoo, K. N., Iagaru, A. n.

The Impact of Post-Operative Therapy on Primary Cardiac Sarcoma The Journal of Thoracic and Cardiovascular Surgery
Wu, Y., Million, L., Moding, E. J., Scott, G., Berry, M., Ganjoo, K. N.

Circulating tumor DNA levels correlate with response to treatment in LMS patients
Przybyl, J., Chabon, J. J., Spans, L., Ganjoo, K., Vennam, S., Newman, A. M., Forgo, E., Varma, S., Zhu, S., Debic-Rychter, M., Alizadeh, A., Diehn, M., van de Rijn, et al

A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma. Rare tumors
Bui, N. n., Kamat, N. n., Ravi, V. n., Chawla, S. n., Lohman, M. n., Ganjoo, K. N.

Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research
Przybyl, J. n., Chabon, J. J., Spans, L. n., Ganjoo, K. n., Vennam, S. n., Newman, A. M., Forgó, E. n., Varma, S. n., Zhu, S. n., Debic-Rychter, M. n., Alizadeh, A. A., Diehn, M. n., van de Rijn, et al

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial GYNECOLOGIC ONCOLOGY
Hensley, M. L., Patel, S. R., von Mehren, M., Ganjoo, K., Jones, R. L., Staddon, A., Rushing, D., Milhem, M., Monk, B., Wang, G., McCarthy, S., Knoblauch, R. E., Parekh, et al

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial LANCET ONCOLOGY
Tap, W. D., Papai, Z., Van Tine, B. A., Attia, S., Ganjoo, K. N., Jones, R. L., Schuetze, S., Reed, D., Chawla, S. P., Riedel, R. F., Krarup-Hansen, A., Toulmonde, M., Ray-Coquard, et al

Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma BRITISH JOURNAL OF HAEMATOLOGY
• Phase III study of aldoxorubicin vs investigators’ choice as treatment for relapsed/refractory soft tissue sarcomas
Chawla, S. P., Ganjoo, K. N., Schuetze, S., Papai, Z., Van Tine, B., Choy, E., Liebner, D. A., Agulnik, M., Chawla, S., Wieland, S., Levitt, D. J.
AMER SOC CLINICAL ONCOLOGY. 2017

• A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARCO24 trial results
Attia, S., Bolejack, V., Ganjoo, K. N., George, S., Agulnik, M., Rushing, D. A., Loggers, E., Livingston, M. B., Wright, J. A., Chawla, S. P., Okuno, S. H., Reinke, D. K., Riedel, et al
AMER SOC CLINICAL ONCOLOGY. 2017

• Improving care with portfolio of physician-led cancer quality measures at an academic center
Porter, J., Smith, A., Winget, M., Rosenthal, E., Seshadri, S., Vetteth, Y., Kiamanesh, E. F., Badwe, A., Advani, R. H., Buyyounouski, M. K., Coutre, S., Dorigo, O., Ganjoo, et al
AMER SOC CLINICAL ONCOLOGY. 2017

• Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study. EUROPEAN RADIOLOGY
Ghanouni, P., Dobrotwir, A., Bazzocchi, A., Bucknor, M., Bitton, R., Rosenberg, J., Telischak, K., Busacca, M., Ferrari, S., Albisinni, U., Walters, S., Gold, G., Ganjoo, et al
2017; 27 (2): 732-740

• Phase 2 Study of Dasatinib in Patients With Alveolar Soft Part Sarcoma, Chondrosarcoma, Chordoma, Epithelioid Sarcoma, or Solitary Fibrous Tumor CANCER
Schuetze, S. M., Bolejack, V., Choy, E., Ganjoo, K. N., Staddon, A. P., Chow, W. A., Tawbi, H. A., Samuels, B. L., Patel, S. R., von Mehren, M., D’Amato, G., Leu, K. M., Loeb, et al
2017; 123 (1): 90-97

• Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors. Sarcoma
Moding, E. J., Million, L., Avedian, R., Ghanouni, P., Kunder, C., Ganjoo, K. N.
2017; 2017: 2316839

• Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center
Porter, J. B.
2017; 13 (8): e673-e682

• Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer
Schuetze, S. M., Bolejack, V., Choy, E., Ganjoo, K. N., Staddon, A. P., Chow, W. A., Tawbi, H. A., Samuels, B. L., Patel, S. R., von Mehren, M., D’Amato, G., Leu, K. M., Loeb, et al
2016

• Soft Tissue Sarcoma, Version 2.2016 Clinical Practice Guidelines in Oncology JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Conrad, E. U., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, J. M., Koon, H., Mayerson, et al
2016; 14 (6): 758-786

• Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study. European radiology
Ghanouni, P., Dobrotwir, A., Bazzocchi, A., Bucknor, M., Bitton, R., Rosenberg, J., Telischak, K., Busacca, M., Ferrari, S., Albisinni, U., Walters, S., Gold, G., Ganjoo, et al
2016: -?

• SARCO09: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer
Schuetze, S. M., Wathen, J. K., Lucas, D. R., Choy, E., Samuels, B. L., Staddon, A. P., Ganjoo, K. N., von Mehren, M., Chow, W. A., Loeb, D. M., Tawbi, H. A., Rushing, D. A., Patel, et al
2016; 122 (6): 868-874

• Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Journal of clinical oncology
Demetri, G. D., von Mehren, M., Jones, R. L., Hensley, M. L., Schuetze, S. M., Staddon, A., Milhem, M., Elias, A., Ganjoo, K., Tawbi, H., Van Tine, B. A., Spira, A., Dean, et al
2016; 34 (8): 786-793

- First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial. JAMA oncology
Chawla, S. P., Papai, Z., Mukhametshina, G., Sankhala, K., Vasylyev, L., Fedenko, A., Khamly, K., Ganjoo, K., Nagarkar, R., Wieland, S., Levitt, D. J.
2015; 1 (9): 1272-1280

- First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma A Phase 2b Randomized Clinical Trial JAMA ONCOLOGY
Chawla, S. P., Papai, Z., Mukhametshina, G., Sankhala, K., Vasylyev, L., Fedenko, A., Khamly, K., Ganjoo, K., Nagarkar, R., Wieland, S., Levitt, D. J.
2015; 1 (9): 1272-1280

- Sarcoma Resection With and Without Vascular Reconstruction: A Matched Case-control Study ANNAALS OF SURGERY
Poultsides, G. A., Tran, T. B., Zambrano, E., Janson, L., Mohler, D. G., Mell, M. W., Avedian, R. S., Visser, B. C., Lee, J. T., Ganjoo, K., Harris, E. J., Norton, J. A.
2015; 262 (4): 632-640

- Sarcoma Resection With and Without Vascular Reconstruction: A Matched Case-control Study. Annals of surgery
Poultsides, G. A., Tran, T. B., Zambrano, E., Janson, L., Mohler, D. G., Mell, M. W., Avedian, R. S., Visser, B. C., Lee, J. T., Ganjoo, K., Harris, E. J., Norton, J. A.
2015; 262 (4): 632-40

- Combined F-18-NaF and F-18-FDG PET/CT in the Evaluation of Sarcoma Patients CLINICAL NUCLEAR MEDICINE
Jackson, T., Mosci, C., von Eyben, R., Mittra, E., Ganjoo, K., Biswal, S., Gambhir, S. S., Iagaru, A.
2015; 40 (9): 720-724

- Denosumab, a Potential Alternative to the Surgical Treatment of Distal Radius Giant Cell Tumor of Bone: Case Report. journal of hand surgery
Park, M. J., Ganjoo, K. N., Ladd, A. L.
2015; 40 (8): 1620-1624

- Clinically Relevant Molecular Subtypes in Leiomyosarcoma. Clinical cancer research
Guo, X., Jo, V. Y., Mills, A. M., Zhu, S. X., Lee, C., Espinosa, I., Nucci, M. R., Varma, S., Forgó, E., Hastie, T., Anderson, S., Ganjoo, K., Beck, et al
2015; 21 (15): 3501-3511

- Leiomyosarcoma: One Disease or Distinct Biologic Entities Based on Site of Origin? JOURNAL OF SURGICAL ONCOLOGY
Worhunsky, D. J., Gupta, M., Gholami, S., Tran, T. B., Ganjoo, K. N., van de Rijn, M., Visser, B. C., Norton, J. A., Poultsides, G. A.
2015; 111 (7): 808-812

- Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity Fc?RIIIa Patients with Previously Treated Follicular Lymphoma. Leukemia & lymphoma
Ganjoo, K. N., de Vos, S., Pohlman, B. L., Flinn, I. W., Forero-Torres, A., Enas, N. H., Cronier, D. M., Dang, N. H., Foon, K. A., Carpenter, S. P., Slapak, C. A., Link, B. K., Smith, et al
2015; 56 (1): 42-48

- Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study ACTA ONCOLOGICA
Martin-Broto, J., Cleeland, C. S., Glare, P. A., Engellau, J., Skubitz, K. M., Blum, R. H., Ganjoo, K. N., Staddon, A., Dominikus, M., Feng, A., Qian, Y., Braun, A., Jacobs, et al
2014; 53 (9): 1173-1179

- Active idiotype vaccination versus control immunotherapy for follicular lymphoma. Journal of clinical oncology
Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., Connors, J. M., Berinstein, N. L., Belch, A. R., Bartlett, N. L., Nichols, C., Emmanouilides, C. E., Timerman, et al
2014; 32 (17): 1797-1803

- Results of SARC 022, a phase II multicenter study of linsitinib in pediatric and adult wild-type (WT) gastrointestinal stromal tumors (GIST).
von Mehren, M., George, S., Heinrich, M. C., Schuetze, S., Belinsky, M. G., Janeway, K. A., Rink, L., Ganjoo, K. N., Yu, J., Yap, J. T., Wright, J., Van den Abbeele, A. D.
AMER SOC CLINICAL ONCOLOGY.2014
• Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leukemia & lymphoma
Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., Swinnen, L. J., Habermann, T. M., Kahl, B. S., Advani, R. H.
2014; 55 (4): 768-772

• Soft tissue sarcoma, version 2.2014. Journal of the National Comprehensive Cancer Network
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, et al.
2014; 12 (4): 473-483

• The Treatment Outcome for Adult Patients with Ewing's Sarcoma. Current oncology reports
Ganjoo, K. N., Patel, S.
2013; 15 (4): 372-377

• Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
Henry, E., Villalobos, V., Million, L., Jensen, K. C., West, R., Ganjoo, K., Lebovson, A., Ford, J. M., Telli, M. L.
2012; 10 (8): 939-942

• Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
von Mehren, M., Benjamin, R. S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., George, S., Gonzalez, R., Heslin, M. J., Kane, J. M., Mayerson, J., McGarry, et al.
2012; 10 (8): 951-960

• Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial LEUKEMIA & LYMPHOMA
Advani, R. H., Hong, F., Horning, S. J., Kahl, B. S., Manola, J., Swinnen, L. J., Habermann, T. M., Ganjoo, K.
2012; 53 (4): 718-720

• Results of a Phase I Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in Fc gamma RIlla-Genotyped Patients with Previously Treated Follicular Lymphoma CLINICAL CANCER RESEARCH
Forero-Torres, A., de Vos, S., Pohlman, B. L., Pashkevich, M., Cronier, D. M., Dang, N. H., Carpenter, S. P., Allan, B. W., Nelson, J. G., Slapak, C. A., Smith, M. R., Link, B. K., Woolridge, et al.
2012; 18 (5): 1395-1403

• Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer CANCER INVESTIGATION
Riess, J. W., Logan, A. C., Krupitskaya, Y., Padda, S., Clement-Duchene, C., Ganjoo, K., Colevas, A. D., San Pedro-Salcedo, M., Kuo, C. J., Wakelee, H. A.
2012; 30 (3): 231-235

• The Prognostic Value of Tumor-Associated Macrophages in Leiomyosarcoma A Single Institution Study AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
Ganjoo, K. N., Witten, D., Patel, M., Espinosa, I., La, T., Tibshirani, R., van de Rijn, M., Jacobs, C., West, R. B.
2011; 34 (1): 82-86

• A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer JOURNAL OF THORACIC ONCOLOGY
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., McMillan, A., Kumar, A., Zhao, G., Padda, S., Zhou, L., San Pedro-Salcedo, M., Colevas, A. D., Wakelee, H. A.
2010; 5 (11): 1821-1825

• TH-302, a tumor selective hypoxia activated prodrug, complements and enhances chemotherapy treatment with gemcitabine, docetaxel, pemetrexed, and doxorubicin 22nd European Organization for Research and Treatment of Cancer (EORTC)-National-Cancer-Institute(NCI)-American-Association-for-Cancer-Research(AACR) Symposium on Molecular Targets and Cancer Therapeutics
Hart, C. P., Borad, M., Chawla, S. P., Infante, J. R., Ganjoo, K. N., Langmuir, V. K., KROLL, S., Curd, J. G.
PERGAMON-ELSEVIER SCIENCE LTD.2010: 124–24

• I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (ZevalinA (R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma MOLECULAR IMAGING AND BIOLOGY
Iagaru, A., Mittra, E. S., Ganjoo, K., Knox, S. J., Goris, M. L.
2010; 12 (2): 198-203
• Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma Results From a Multicenter Study. CANCER
Kahl, B. S., Bartlett, N. L., Leonard, J. P., Chen, L., Ganjoo, K., Williams, M. E., Czuczman, M. S., Robinson, K. S., Joyce, R., Van der Jagt, R. H., Cheson, B. D. 2010; 116 (1): 106-114

• Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor. Case reports in oncology
Brar, R., West, R., Witten, D., Raman, B., Jacobs, C., Ganjoo, K. 2009; 2 (3): 242-250

• Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CROP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial.
Advani, R. H., Hong, F., Ganjoo, K. N., Manola, J. B., Swinnen, L. J., Habermann, T. M., Horning, S. J. AMER SOC HEMATOLOGY.2009: 667

• Mid-treatment PET predicts progression in hypofractionated accelerated radiation therapy for lung tumors
Chang, C. N., Fillion, E., Chapman, C., Rao, A., Wakelee, H., Ganjoo, K., Le, Q., Maxim, P., Quon, A., Graves, E. E., Loo, B. W. LIPPINCOTT WILLIAMS & WILKINS.2009: S939–S939

• A phase II first line study of gemcitabine, carboplatin and bevacizumab in advanced stage non-squamous non-cell lung cancer
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., Kumar, A., Zhao, G., Padda, S., San Pedro-Salcedo, M., Wakelee, H. LIPPINCOTT WILLIAMS & WILKINS.2009: S674–S674

• Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma. AMERICAN JOURNAL OF PATHOLOGY
Espinosa, I., Beck, A. H., Lee, C., Zhu, S., Montgomery, K. D., Marinelli, R. J., Ganjoo, K. N., Nielsen, T. O., Gilks, C. B., West, R. B., van de Rijn, M. 2009; 174 (6): 2347-2356

• Opportunistic enteroviral meningoencephalitis: an unusual treatable complication of rituximab therapy. LEUKEMIA & LYMPHOMA
Ganjoo, K. N., Raman, R., Sobel, R. A., Pinto, H. A. 2009; 50 (4): 673-675

• Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor. CASE REPORTS IN ONCOLOGY
Brar, R., West, R., Witten, D., Raman, B., Jacobs, C., Ganjoo, K. 2009; 2 (3): 242–50

• Breast angiosarcomas: Case series and expression of vascular endothelial growth factor. Case Reports in Oncology
Rondeep Brar, Robert West, Daniela Witten, Bhargav Raman, Charlotte Jacobs, Kristen Ganjoo 2009; 2: 242-50

• Preliminary results of a Phase I study of AME-133v, an Fc-engineered humanized monoclonal antibody, in low-affinity Fc gamma RIHa patients with previously-treated follicular lymphoma
Forero, A., de Vos, S., Pohlman, B., Enas, N., Ganjoo, K. N., Cronier, D., Dang, N. H., Carpenter, S. P., Smith, M. R., Lin, B. K., Wooldridge, J. E. AMER ASSOC CANCER RESEARCH.2008

• Results of a Phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotypic (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymph
Levy, R., Robertson, M. J., Ganjoo, K., Leonard, J., Vose, J., Denney, D. AMER ASSOC CANCER RESEARCH.2008

• The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Ganjoo, K. N., Moore, A. M., Orazi, A., Sen, J. A., Johnson, C. S., An, C. S. 2008; 134 (3): 381-387

• Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics: Targets & Therapy
Kristen N Ganjoo, Heather Wakelee 2008

• Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics : targets & therapy
Ganjoo, K. N., Wakelee, H.
• Comparison of I-131-Tositumomab (Bexxar (R)) and Y-90-Ibritumomab (Zevalin (R)) therapy of refractory/relapsed non-Hodgkin lymphoma
Iagaru, A., Zhu, H., Mari, C., Knox, S. J., Ganjoo, K., Goris, M. L.
SPRINGER.2007: S168

• Non-Hodgkin lymphoma of the breast CANCER
Ganjoo, K., Advani, R., Mariappan, M. R., McMillan, A., Horning, S.
2007; 110 (1): 25-30

• Antiangiogenesis: A new approach to the treatment of lymphoma LEUKEMIA & LYPHOMA
Ganjoo, K.
2007; 48 (3): 454-455

• Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis LEUKEMIA & LYPHOMA
Ganjoo, K. N., An, C. S., Robertson, M. J., Gordon, L. I., Sen, J. A., Weisenbach, J., Li, S., Weller, E. A., Orazi, A., Horning, S. J.
2006; 47 (6): 998-1005

• Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia CANCER
Frankel, A. E., Surendranathan, A., Black, J. H., White, A., Ganjoo, K., Cripe, L. D.
2006; 106 (10): 2158-2164

• A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas - A hoosier oncology group study AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
Ganjoo, K. N., Robertson, M. J., Fisher, W., Jung, S. H., McClean, J., Huh, S. Y., Bufill, J., Williams, S., Cripe, L. D.
2005; 28 (2): 169-172

• Unusual locations of involvement by malignancies - Case 1. Testicular plasmacytoma JOURNAL OF CLINICAL ONCOLOGY
Shafqat, A., Yum, M. N., Abanour, R., Ganjoo, K. N.
2003; 21 (17): 3368-3369

• Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A Hoosier Oncology Group study ONCOLOGY
Schneider, B. P., Ganjoo, K. N., Seitz, D. E., Picus, J., Fata, F., Stoner, C., Calley, C., Loehrer, P. J.
2003; 65 (3): 218-223

• A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: A Hoosier Oncology Group study ONCOLOGY
Ganjoo, K. N., GORDON, M. S., Sandler, A. B., Warner, R. E., Fife, K., Poirier, S., Seshadri, R., Loehrer, P. J.
2002; 62 (4): 299-304

• Germ cell tumor associated primitive neuroectodermal tumors JOURNAL OF UROLOGY
Ganjoo, K. N., Foster, R. S., Michael, H., Donohue, J. P., Einhorn, L. H.
2001; 165 (5): 1514-1516

• Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors 35th Annual Meeting of the American-Society-of-Clinical-Oncology
Ganjoo, K. N., Rieger, K. M., Kesler, K. A., Sharma, M., Heilman, D. K., Einhorn, L. H.
JOHN WILEY & SONS INC.2000: 1051–56

• Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma 35th Annual Meeting of the American-Society-of-Clinical-Oncology
Ganjoo, K. N., Chan, R. J., Sharma, M., Einhorn, L. H.
AMER SOC CLINICAL ONCOLOGY.1999: 3457–60

• Primary mediastinal nonseminomatous germ cell tumors: The influence of postchemotherapy pathology on long-term survival after surgery 79th Annual Meeting of the American-Association-for-Thoracic-Surgery
Kesler, K. A., Rieger, K. M., Ganjoo, K. N., Sharma, M., Fineberg, N. S., Einhorn, L. H., Brown, J. W.
MOSBY-ELSEVIER.1999: 692–700

• Lung cancer presenting with solitary bone metastases - Case 1: Metastatic adenocarcinoma to the patella JOURNAL OF CLINICAL ONCOLOGY
Ganjoo, K. N., Loyal, J. A., Cramer, H. M., Loehrer, P. J.
Endometriosis Malignant Transformation Review: Rhabdomyosarcoma Arising From an Endometrioma. JSLS: Journal of the Society of Laparoendoscopic Surgeons

Nezhat, C. n., Vu, M. n., Vang, N. n., Ganjoo, K. n., Karam, A. n., Folkins, A. n., Nezhat, A. n., Nezhat, F. n.

; 23 (4)